New heart failure drug shows early promise in safety trial

NCT ID NCT05328752

Completed Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called XXB750 in 27 adults with stable heart failure and reduced heart pumping ability. The main goal was to see if the drug is safe and tolerable. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moves through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) OR HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION (HFMREF)

Contacts and locations

Locations

Fairview Health Services .

Saint Paul, Minnesota, 55102, United States
Jacksonville Ctr for Clin Rea Main Centre

Jacksonville, Florida, 32216, United States
Nature Coast Clinical Research LLC

Inverness, Florida, 34452, United States
Novartis Investigative Site

Groningen, 9713 GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.